Bal Pharma Limited has informed the Exchange regarding a press release dated September 28, 2021, titled "Bal Pharma poised to strengthen its position in diabetes segment through its Active Pharmaceutical ingredient ( API) Gliclazide.".
Press Release Sep 28 2021
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Bal Pharma
Later from Bal Pharma
- Press Release Nov 15 2021
- Press Release Feb 11 2022
- Press Release Feb 24 2022
- Press Release May 31 2022
- Press Release Aug 12 2022
Follow Bal Pharma into a list and get an email when it puts out news.
Follow Bal Pharma